Developing New Antibody Treatments for Cancer
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.
This research aims to create highly specific antibody-based treatments that can target cancer cells while leaving healthy cells unharmed, particularly for acute leukemia.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11109600 on NIH RePORTER |
What this research studies
Our long-standing goal is to find clear differences between cancer cells and healthy cells to develop safe and effective new immune-based therapies. We are building on decades of work, evolving from early antibody treatments to more advanced forms like BiTEs and CAR technologies. This project focuses on creating special antibodies that can mimic how the body's own immune T cells recognize and fight cancer. By doing so, we hope to develop treatments that are truly selective for cancer.
Who could benefit from this research
Good fit: This foundational research is focused on developing new therapies for cancers, particularly acute leukemia, and is not yet recruiting specific patients.
Not a fit: Patients seeking immediate treatment options may not directly benefit from this early-stage research, which focuses on developing future therapies.
Why it matters
Potential benefit: If successful, this work could lead to new, highly targeted immunotherapies that are more effective and have fewer side effects for patients with cancers like acute leukemia.
How similar studies have performed: The principal investigator's prior work has led to numerous therapeutic firsts, including human antibodies for acute leukemia and targeted alpha-particle therapies, with some reaching late-stage clinical trials.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Scheinberg, David a — Sloan-Kettering Inst Can Research
- Study coordinator: Scheinberg, David a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.